Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism

Gualtiero Palareti, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Angelo A Bignamini, Corrado Lodigiani, Alberto Tosetto, Lorenza Bertù, Vittorio Pengo, Sophie Testa, Walter Ageno, Domenico Prisco, Paolo Prandoni, Daniela Poli, Gualtiero Palareti, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Angelo A Bignamini, Corrado Lodigiani, Alberto Tosetto, Lorenza Bertù, Vittorio Pengo, Sophie Testa, Walter Ageno, Domenico Prisco, Paolo Prandoni, Daniela Poli

Abstract

How to prevent recurrences after a first venous thromboembolic (VTE) event in elderly patients is still an open issue, especially because of the high bleeding risk of anticoagulation in these patients. The placebo-controlled "Jason" study aims at assessing the efficacy and safety for secondary VTE prevention in elderly patients of oral Sulodexide (Vessel®) administration, a mixture of glycosaminoglycans (Alfasigma, Bologna, Italy) which proved effective against recurrences in a general population (SURVET study) without major bleeding (MB) complications. 1450 patients, aged ≥ 75 years, after at least 3 months of anticoagulation treatment for a first VTE episode, are double-blind randomized to receive for 12 months either sulodexide 500 lipasemic units (LSUs) twice daily, or sulodexide 250 LSU twice daily + indistinguishable placebo, or indistinguishable placebo. Primary outcomes for efficacy are the composite of death for VTE and recurrent VTE, and occurrence of MB for safety. Secondary outcomes include stroke, cardiovascular death and other thromboembolic events, and MB + clinically relevant non-MB. The first patient is scheduled to be randomized in May 2020. The study protocol has been approved by AIFA (Agenzia Italiana del Farmaco) and the Ethics Committee of the coordinating center. Written informed consent will be obtained from all patients prior to study participation. Jason study is an investigator-initiated trial, promoted by "Arianna Anticoagulazione" Foundation, Bologna, Italy, and supported by Alfasigma, Bologna, Italy. Study findings will be disseminated to participant centers, at research conferences and in peer-reviewed journals. Trial registration numbers NCT04257487; EudraCT (2019-000570-33).

Keywords: Elderly; Extension; Recurrence; Sulodexide; Venous thromboembolism.

Conflict of interest statement

G. Palareti has sat on advisory boards for Alfasigma, Pfizer, BMS and Roche. None Declared for all other Authors.

Figures

Fig. 1
Fig. 1
Flow chat Jason study

References

    1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–893. doi: 10.1001/archinte.158.6.585.
    1. Oger E. Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost. 2000;83:657–660. doi: 10.1055/s-0037-1613887.
    1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14. doi: 10.1007/s11239-015-1311-6.
    1. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352. doi: 10.1016/j.chest.2015.11.026.
    1. Lauber S, Limacher A, Tritschler T, Stalder O, Mean M, Righini M, Aschwanden M, Beer JH, Frauchiger B, Osterwalder J, Kucher N, Lammle B, Cornuz J, Angelillo-Scherrer A, Matter CM, Husmann M, Banyai M, Staub D, Mazzolai L, Hugli O, Rodondi N, Aujesky D. Predictors and outcomes of recurrent venous thromboembolism in elderly patients. Am J Med. 2018;131:703. doi: 10.1016/j.amjmed.2017.12.015.
    1. Palareti G, Legnani C, Antonucci E, Cosmi B, Poli D, Testa S, Tosetto A, Ageno W, Falanga A, Ferrini PM, Pengo V, Prandoni P. DD-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. Intern Emerg Med. 2019 doi: 10.1007/s11739-019-02216-y.
    1. Tosetto A, Testa S, Martinelli I, Poli D, Cosmi B, Lodigiani C, Ageno W, De Stefano V, Falanga A, Nichele I, Paoletti O, Bucciarelli P, Antonucci E, Legnani C, Banfi E, Dentali F, Bartolomei F, Barcella L, Palareti G. External validation of the DASH prediction rule: a retrospective cohort study. J Thromb Haemost. 2017;15:1963–1970. doi: 10.1111/jth.13781.
    1. Siguret V, Emmerich J, Belleville T, Golmard JL, Mazoyer E, Gouin-Thibault I, Pautas E. Prevalence of hereditary thrombophilia in patients older than 75 years with venous thromboembolism referred for thrombophilia screening. J Gerontol A Biol Sci Med Sci. 2020;70:977–981. doi: 10.1093/gerona/glu240.
    1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism (2015) N Engl J Med. 2013;368:699–708. doi: 10.1056/NEJMoa1207541.
    1. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–1222. doi: 10.1056/NEJMoa1700518.
    1. Andreozzi GM, Bignamini AA, Davi G, Palareti G, Matuska J, Holy M, Pawlaczyk-Gabriel K, Dzupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Visona A, Investigators SS. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132:1891–1897. doi: 10.1161/CIRCULATIONAHA.115.016930.
    1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694. doi: 10.1111/j.1538-7836.2005.01204.x.
    1. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of A Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119–2126. doi: 10.1111/jth.13140.
    1. Villalta SBP, Piccioli A, Lensing AWA, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis. 1994;24(1 Suppl):158a.
    1. Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P, Noventa F, Benedetti L, Girolami A. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation. 1993;88:1730–1735. doi: 10.1161/01.CIR.88.4.1730.
    1. Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med. 2003;349:1247–1256. doi: 10.1056/NEJMcp035442.
    1. Kearon C. Diagnosis of pulmonary embolism. Can Med Assoc J. 2003;168:183–194.
    1. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–191. doi: 10.3758/BF03193146.
    1. Zhang E, Wu VQ, Chow S-C, Zhang HG. TrialSize: r functions In: in Chapter 3,4,6,7,9,10,11,12,14,15 2013.
    1. Eischer L, Eichinger S, Kyrle PA. Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. Medicine (Baltimore) 2009;88:366–370. doi: 10.1097/MD.0b013e3181c29e31.
    1. Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, Gurwitz JH, Goldberg RJ. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost. 2008;100:780–788. doi: 10.1160/TH08-04-0255.
    1. Spencer FA, Gurwitz JH, Schulman S, Linkins LA, Crowther MA, Ginsberg JS, Lee AY, Saczynski JS, Anand S, Lessard D, Emery C, Huang W, Goldberg RJ. Venous thromboembolism in older adults: a community-based study. Am J Med. 2014;127:530–5377. doi: 10.1016/j.amjmed.2014.02.011.
    1. Vasco B, Villalba JC, Lopez-Jimenez L, Falga C, Montes J, Trujillo-Santos J, Monreal M. Venous thromboembolism in nonagenarians. Findings from the RIETE registry. Thromb Haemost. 2009;101:1112–1118. doi: 10.1160/TH08-12-0827.
    1. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin k antagonist treatment: results of a prospective collaborative study on elderly patients followed by italian centres for anticoagulation. Circulation. 2011;124:824–859. doi: 10.1161/CIRCULATIONAHA.110.007864.
    1. Faller N, Limacher A, Mean M, Righini M, Aschwanden M, Beer JH, Frauchiger B, Osterwalder J, Kucher N, Lammle B, Cornuz J, Angelillo-Scherrer A, Matter CM, Husmann M, Banyai M, Staub D, Mazzolai L, Hugli O, Rodondi N, Aujesky D. Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: a prospective cohort study. Am J Med. 2017;130:198–206. doi: 10.1016/j.amjmed.2016.09.008.
    1. Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014;124:196–203. doi: 10.1182/blood-2014-01-548065.
    1. van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968–1975.
    1. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. doi: 10.1056/NEJMoa1302507.
    1. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510. doi: 10.1056/NEJMoa1007903.
    1. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297. doi: 10.1056/NEJMoa1113572.
    1. Iacoviello L, Dadamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost. 1996;76:1102–1107. doi: 10.1055/s-0038-1650713.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner